alantolactone has been researched along with olaparib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, X; Cheng, YJ; Ding, C; He, JX; Jia, L; Kayumov, M; Miao, ZH; Mirzaakhmedov, S; Pardaev, A; Song, SS; Zhang, A; Zhang, RI | 1 |
| Larrosa, I; Osborne, HC; Schmidt, CK | 1 |
2 other study(ies) available for alantolactone and olaparib
| Article | Year |
|---|---|
Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactone.
Topics: Apoptosis; Biological Products; Cell Line, Tumor; G2 Phase Cell Cycle Checkpoints; Humans; Lactones; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Sesquiterpenes, Eudesmane | 2022 |
Sesquiterpene Lactones Potentiate Olaparib-Induced DNA Damage in p53 Wildtype Cancer Cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromosomal Instability; Dose-Response Relationship, Drug; Drug Synergism; Humans; Lactones; Neoplasms; Oxidative Stress; Phthalazines; Piperazines; Pyrazoles; Pyrimidinones; Sesquiterpenes; Sesquiterpenes, Eudesmane; Tumor Suppressor Protein p53 | 2022 |